Get the Stockscreener App
13.00
0.62%
0.08
Tenax Therapeutics Inc stock is traded at $13.00, with a volume of 33,027.
It is up +0.62% in the last 24 hours and down -13.62% over the past month.
Tenax Therapeutics Inc is a specialty pharmaceutical company focused on identifying, developing, and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical needs. The company owns North American rights to develop and commercialize levosimendan and has released topline data regarding the Phase 2 clinical trial for the use of levosimendan in the treatment of pulmonary hypertension associated with Heart Failure and preserved Ejection Fraction.
See More
Previous Close:
$12.92
Open:
$12.88
24h Volume:
33,027
Relative Volume:
0.15
Market Cap:
$81.17M
Revenue:
-
Net Income/Loss:
$-14.56M
P/E Ratio:
-0.7729
EPS:
-16.82
Net Cash Flow:
$-12.46M
1W Performance:
+2.12%
1M Performance:
-13.62%
6M Performance:
+119.97%
1Y Performance:
+78.08%
1-Day Range:
$12.66
$13.32
1-Week Range:
$12.53
$14.08
52-Week Range:
$4.63
$18.38
Tenax Therapeutics Inc Stock (TENX) Company Profile
Name
Tenax Therapeutics Inc
Sector
Industry
Phone
919-855-2100
Address
101 GLEN LENNOX DRIVE, CHAPEL HILL, NC
Compare TENX vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TENX
Tenax Therapeutics Inc
|
13.00 | 80.67M | 0 | -14.56M | -12.46M | -16.82 |
|
VRTX
Vertex Pharmaceuticals Inc
|
495.97 | 117.98B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
799.96 | 82.85B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
846.57 | 51.58B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
311.38 | 40.75B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
350.03 | 38.33B | 4.98B | 69.60M | 525.67M | 0.5198 |
Tenax Therapeutics Inc Stock (TENX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-08-25 | Initiated | Piper Sandler | Overweight |
| Oct-24-24 | Initiated | Leerink Partners | Outperform |
| Oct-14-24 | Initiated | Guggenheim | Buy |
| Sep-30-24 | Initiated | William Blair | Outperform |
| May-18-17 | Upgrade | Ladenburg Thalmann | Neutral → Buy |
| Dec-16-14 | Initiated | MLV & Co | Buy |
| Nov-18-14 | Initiated | WallachBeth | Buy |
View All
Tenax Therapeutics Inc Stock (TENX) Latest News
Tenax Therapeutics (NASDAQ:TENX) Stock Passes Above 200 Day Moving AverageWhat's Next? - MarketBeat
Will Tenax Therapeutics Inc. outperform tech stocksJuly 2025 Summary & Risk Adjusted Buy and Sell Alerts - mfd.ru
Responsive Playbooks and the TENX Inflection - Stock Traders Daily
Bear Alert: What hedge funds are buying Tenax Therapeutics IncWeekly Earnings Recap & Consistent Profit Focused Trading Strategies - baoquankhu1.vn
Tenax Therapeutics (NASDAQ:TENX) Shares Pass Above 200 Day Moving AverageShould You Sell? - MarketBeat
Tenax Therapeutics (NASDAQ:TENX) Shares Pass Above 200 Day Moving Average – Should You Sell? - Defense World
Tenax Therapeutics to Participate in the Guggenheim Emerging Outlook Biotech Summit 2026 - Investing News Network
Risk Report: Is Harris Oakmark Etf Trust stock a hidden gemQuarterly Trade Summary & Weekly Breakout Opportunity Watchlist - baoquankhu1.vn
Fundamentals Check: What is the next catalyst for Tenax Therapeutics IncPortfolio Return Summary & AI Forecasted Stock Moves - baoquankhu1.vn
Is Tenax Therapeutics Inc. still a buy after recent gains2025 Market Overview & Safe Capital Growth Tips - mfd.ru
Understanding the Setup: (TENX) and Scalable Risk - Stock Traders Daily
Tenax Therapeutics (NASDAQ:TENX) Shares Pass Above 200-Day Moving AverageHere's Why - MarketBeat
Aug Macro: Is Tenax Therapeutics Inc forming a double bottomWall Street Watch & Proven Capital Preservation Tips - baoquankhu1.vn
Aug Movers: Will CPSP face regulatory challengesTrade Risk Assessment & Risk Managed Investment Entry Signals - baoquankhu1.vn
Financial Survey: Biorestorative Therapies (NASDAQ:BRTX) vs. Tenax Therapeutics (NASDAQ:TENX) - Defense World
The Technical Signals Behind (TENX) That Institutions Follow - Stock Traders Daily
Investment Review: Can Tenax Therapeutics Inc stock outperform in 2025 bull marketPortfolio Growth Summary & Low Drawdown Investment Strategies - Bộ Nội Vụ
Published on: 2026-01-14 00:08:43 - Bộ Nội Vụ
Tenax Therapeutics (NASDAQ:TENX) Share Price Passes Above Two Hundred Day Moving AverageHere's What Happened - MarketBeat
Tenax Therapeutics (NASDAQ:TENX) Is In A Good Position To Deliver On Growth Plans - Sahm
Guggenheim doubles Tenax (TENX) PT, names stock top pick - MSN
Tenax Therapeutics Stock: A Speculative Buy (NASDAQ:TENX) - Seeking Alpha
How Tenax Therapeutics Inc. stock reacts to oil prices2025 Trading Recap & Real-Time Stock Entry Alerts - Улправда
Is Tenax Therapeutics Inc. stock cheap at current valuationJuly 2025 Selloffs & Daily Profit Maximizing Tips - Улправда
Why Tenax Therapeutics Inc. stock is considered a top pickJuly 2025 Big Picture & AI Forecasted Stock Moves - ulpravda.ru
Guggenheim Doubles Tenax (TENX) PT, Names Stock Top Pick - Finviz
Will Tenax Therapeutics Inc. stock see insider buyingRisk Management & Low Drawdown Trading Techniques - Улправда
Earnings Beat: Is Tenax Therapeutics Inc. stock overvalued by current metrics2025 Support & Resistance & Risk Managed Investment Signals - Улправда
Is Tenax Therapeutics Inc. stock near bottom after declineWeekly Trend Report & Low Volatility Stock Suggestions - Улправда
What is the fair value of Tenax Therapeutics Inc. stock nowEarnings Performance Report & Real-Time Buy Signal Notifications - Улправда
Precision Trading with Tenax Therapeutics Inc. (TENX) Risk Zones - Stock Traders Daily
Tenax Therapeutics: How Lower Variance In Phase 3 Has "Loaded The Dice" For An Asymmetric Repricing - Seeking Alpha
12 Health Care Stocks Moving In Monday's Pre-Market Session - Benzinga
Tenax Therapeutics (NASDAQ:TENX) Stock Price Crosses Above 200 Day Moving AverageHere's Why - MarketBeat
Tenax Therapeutics Inc. (TENX) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
How Tenax Therapeutics Inc. (TENX) Affects Rotational Strategy Timing - Stock Traders Daily
Tenax Therapeutics (NASDAQ:TENX) Stock Crosses Above 200-Day Moving AverageHere's What Happened - MarketBeat
Growth Value: Will Tenax Therapeutics Inc stock see insider buyingGold Moves & Low Risk Growth Stock Ideas - Bộ Nội Vụ
Tenax Therapeutics (TENX) Price Target Increased by 12.22% to 25.76 - Nasdaq
Is Tenax Therapeutics Inc. stock overvalued by current metricsJuly 2025 Spike Watch & Fast Exit and Entry Strategy Plans - DonanımHaber
Roth MKM Reaffirms Their Buy Rating on Tenax Therapeutics (TENX) - The Globe and Mail
Is Tenax Therapeutics Inc. stock supported by strong cash flowsMarket Movers & Low Drawdown Investment Ideas - DonanımHaber
Tenax Therapeutics (NASDAQ:TENX) Stock Crosses Above 200 Day Moving Average – What’s Next? - Defense World
Can Tenax Therapeutics Inc. stock beat market expectations this quarter2025 Technical Patterns & Safe Capital Growth Stock Tips - Улправда
Tenax Therapeutics (NASDAQ:TENX) Stock Crosses Above 200 Day Moving AverageWhat's Next? - MarketBeat
Guggenheim Maintains Tenax Therapeutics (TENX) Buy Recommendation - Nasdaq
Tenax Therapeutics’ phase 3 LEVEL study confirms enrollment target By Investing.com - Investing.com Canada
[8-K] TENAX THERAPEUTICS, INC. Reports Material Event | TENX SEC FilingForm 8-K - Stock Titan
Tenax Therapeutics (TENX) Updates on Clinical Trials and New Ini - GuruFocus
Tenax Therapeutics’ phase 3 LEVEL study confirms enrollment target - Investing.com
Tenax Therapeutics level trial on track to complete enrollment in H1 2026 - marketscreener.com
Tenax Therapeutics Inc Stock (TENX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Tenax Therapeutics Inc Stock (TENX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Rich Stuart | Chief Medical Officer |
Dec 08 '25 |
Buy |
10.10 |
2,500 |
25,250 |
5,000 |
| Rich Stuart | Chief Medical Officer |
Dec 04 '25 |
Buy |
9.20 |
2,500 |
22,998 |
2,500 |
| Rich Stuart | Chief Medical Officer |
Dec 03 '25 |
Buy |
9.08 |
1,500 |
13,618 |
2,766 |
| Rich Stuart | Chief Medical Officer |
Dec 02 '25 |
Buy |
9.01 |
1,000 |
9,006 |
1,266 |
| Giordano Christopher Thomas | CEO |
Nov 18 '25 |
Buy |
7.75 |
1,612 |
12,500 |
1,612 |
| Giordano Christopher Thomas | CEO |
Nov 20 '25 |
Buy |
7.59 |
538 |
4,083 |
2,605 |
| Giordano Christopher Thomas | CEO |
Nov 19 '25 |
Buy |
7.51 |
455 |
3,417 |
2,067 |
| MCGAULEY THOMAS | Interim CFO |
Nov 17 '25 |
Buy |
7.25 |
6,000 |
43,490 |
5,000 |
| MCGAULEY THOMAS | Interim CFO |
Nov 17 '25 |
Buy |
7.34 |
2,000 |
14,674 |
2,000 |
| Almenoff June Sherie | Director |
Nov 18 '25 |
Buy |
7.52 |
1,900 |
14,280 |
1,993 |
0.71%
1.30%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):